Zobrazeno 51 - 60
of 114
pro vyhledávání: '"John Scholler"'
Autor:
John Scholler, Dana L Schalk, Lawrence G. Lum, Archana Thakur, Edwin T. Bliemeister, Ewa Kubicka, Carl H. June
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Adoptive T cell therapies for solid tumors is challenging. We generated metabolically enhanced co-activated-T cells by transducing intracellular co-stimulatory (41BB, ICOS or ICOS-27) and CD3ζ T cell receptor signaling domains followed by arming wit
Autor:
Mark H. O'Hara, Chong Xu, Adham S. Bear, Benjamin A. Garcia, Robert H. Vonderheide, Beatriz M. Carreno, Khatuna Gabunia, Christina Costeas, John Scholler, Avery D. Posey, Michael J. Ford, Sarah McCuaig, Tatiana Blanchard, Smole Anze, Gerald P. Linette, Daniel J. Powell, Miren L. Baroja, Joseph Cesare, Lee P. Richman
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal tumor types. Emerging evidence suggests mutant KRAS (mKRAS) may be targeted immunologically, b
Autor:
Caroline Anna Markmann, Zheng Zheng, Ming Yu, Susan Rostami, Wei Wang, Trini Ochoa, Kalpana Parvathaneni, Xiaoming Xu, John Scholler, Qian Zhang, Avery Posey, David Allman, Michael Milone, Valder Arruda, Ben Samelson Jones, Ali Naji, Vijay Bhoj
Publikováno v:
The Journal of Immunology. 208:175.23-175.23
Pre-existing allo-antibodies (allo-Abs), that preclude transplant due to the risk of hyperacute rejection, lead to prolonged wait times and high mortality rates. Current desensitization approaches are ineffective as they do not adequately deplete all
Autor:
Huaishan Wang, Hui Chen, Shujing Liu, Jie Zhang, Hezhe Lu, Rajasekharan Somasundaram, Robin Choi, Gao Zhang, Lingling Ou, John Scholler, Shifu Tian, Liyun Dong, Guo Yeye, Lili Huang, Thomas Connelly, Ling Li, Alexander Huang, Tara C Mitchell, Yi Fan, Carl H June, Gordon B Mills, Wei Guo, Meenhard Herlyn, Xiaowei Xu
Publikováno v:
Journal for Immunotherapy of Cancer
BackgroundGamma delta (γδ) T cells are attractive effector cells for cancer immunotherapy. Vδ2 T cells expanded by zoledronic acid (ZOL) are the most commonly used γδ T cells for adoptive cell therapy. However, adoptive transfer of the expanded
Autor:
Tong Da, Elizabeth L. Buza, John Scholler, Carl H. June, Caroline Sands, Yangbing Zhao, Joseph A. Fraietta, Kathleen Graham, Mauro Castellarin
Publikováno v:
JCI Insight
Off-tumor targeting of human antigens is difficult to predict in preclinical animal studies and can lead to serious adverse effects in patients. To address this, we developed a mouse model with stable and tunable human Her2 (hHer2) expression on norm
Publikováno v:
J Cancer Res Clin Oncol
PURPOSE: Although adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells has shown durable clinical efficacy in patients with CD19(+) B-cell malignancies, the application of this approach to solid tumors is challenging. The goa
Autor:
Khatuna Gabunia, Stephen J. Schuster, Noelle V. Frey, David L. Porter, Nektarios Kostopoulos, Simon F. Lacey, Carl H. June, Andrea Facciabene, Raymone Pajarillo, Mireia Uribe-Herranz, Vijay Bhoj, Guido Ghilardi, Kalpana Parvathaneni, Elise A. Chong, John Scholler, Marco Ruella, Silvia Beghi, Yong Gu Gu Lee, Kimberly Amelsberg
Publikováno v:
Blood. 138:163-163
Background: Chimeric Antigen Receptor (CAR) T cell immunotherapy has revolutionized the treatment of B-cell malignancies. However, a significant subset of these patients either fails to respond or eventually relapses. Moreover, in solid cancers, CAR
Autor:
Brian Keith, Yangbing Zhao, John Scholler, Carl H. June, Regina M. Young, Biliang Hu, Jiangtao Ren, Yanping Luo
Publikováno v:
Cell reports
Cell Reports, Vol 20, Iss 13, Pp 3025-3033 (2017)
Cell Reports, Vol 20, Iss 13, Pp 3025-3033 (2017)
SUMMARY The effects of transgenically encoded human and mouse IL-18 on T cell proliferation and its application in boosting chimeric antigen receptor (CAR) T cells are presented. Robust enhancement of proliferation of IL-18-secreting human T cells oc
Autor:
Tatiana Blanchard, John Scholler, Robert H. Vonderheide, Beatriz M. Carreno, Mark H. O'Hara, Adham S. Bear, Gerald P. Linette
Publikováno v:
Cancer Research. 81:1899-1899
Activating missense mutations within RAS oncogenes are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal tumor types. Emerging evidence suggests mutant KRAS (mKRAS) may be targeted i
Publikováno v:
Journal of the American College of Surgeons. 231:S34-S35